Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ricolinostat - Regenacy Pharmaceuticals

Drug Profile

Ricolinostat - Regenacy Pharmaceuticals

Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Malignant melanoma; Peripheral nervous system diseases
  • No development reported Breast cancer; Chronic lymphocytic leukaemia

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 07 Nov 2019 Phase-I development is ongoing for Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater), Peritoneal cancer (Combination therapy, Recurrent, Second-line therapy or greater) and Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (NCT02661815)
  • 07 Nov 2019 Celgene and Dana Farber Cancer Institute terminate a phase Ib trial in Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater), Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) and Peritoneal cancer (Combination therapy, Recurrent, Second-line therapy or greater) (owing to company reluctance for further accrual) in USA (PO) (NCT02661815)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top